The remarkable efficacy observed in this case of poorly differentiated pancreatic cancer, which is typically characterized by the high expression of PD-L1, suggests that the combination of nivolumab and metformin may offer a promising therapeutic strategy for specific molecular subtypes of pancreatic cancer. Here, CD274 is linked to familial pancreatic carcinoma.